Cargando…
OCT1-target neural gene PFN2 promotes tumor growth in androgen receptor-negative prostate cancer
Androgen and androgen receptor (AR) targeted therapies are the main treatment for most prostate cancer (PC) patients. Although AR signaling inhibitors are effective, tumors can evade this treatment by transforming to an AR-negative PC via lineage plasticity. OCT1 is a transcription factor interactin...
Autores principales: | Obinata, Daisuke, Funakoshi, Daigo, Takayama, Kenichi, Hara, Makoto, Niranjan, Birunthi, Teng, Linda, Lawrence, Mitchell G., Taylor, Renea A., Risbridger, Gail P., Suzuki, Yutaka, Takahashi, Satoru, Inoue, Satoshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9005514/ https://www.ncbi.nlm.nih.gov/pubmed/35413990 http://dx.doi.org/10.1038/s41598-022-10099-x |
Ejemplares similares
-
Recent Discoveries in the Androgen Receptor Pathway in Castration-Resistant Prostate Cancer
por: Obinata, Daisuke, et al.
Publicado: (2020) -
Crosstalk of the Androgen Receptor with Transcriptional Collaborators: Potential Therapeutic Targets for Castration-Resistant Prostate Cancer
por: Obinata, Daisuke, et al.
Publicado: (2017) -
SAT-330 Preclinical Screen of Patient CRPC Tumors Shows Sensitivity to Bromodomain Inhibitors Includes AR-null and Neuroendocrine Disease
por: Risbridger, Gail, et al.
Publicado: (2019) -
CLDN8, an androgen‐regulated gene, promotes prostate cancer cell proliferation and migration
por: Ashikari, Daisaku, et al.
Publicado: (2017) -
Alterations in the methylome of the stromal tumour microenvironment signal the presence and severity of prostate cancer
por: Lawrence, Mitchell G., et al.
Publicado: (2020)